World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: WHO; 2024.
Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis. 2025;25:1033–43. https://doi.org/10.1016/S1473-3099(25)00118-5.
Kubin CJ, Garzia C, Uhlemann AC. Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations. Antimicrob Agents Chemother. 2025;69:e0106324 https://doi.org/10.1128/aac.01063-24.
Thacharodi A, Vithlani A, Hassan S, Alqahtani A, Pugazhendhi A. Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens. iScience. 2024;27:111367 https://doi.org/10.1016/j.isci.2024.111367.
Zhang S, Di L, Qi Y, Qian X, Wang S. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Front Cell Infect Microbiol. 2024;14:1395260 https://doi.org/10.3389/fcimb.2024.1395260.
CDC. Antibiotic resistance threats in the United States, 2019. 2019. https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html.
Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics. 2020;9. https://doi.org/10.3390/antibiotics9030119.
Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect. 2015;17:173–83. https://doi.org/10.1016/j.micinf.2015.01.004.
Siegel SJ, Weiser JN. Mechanisms of bacterial colonization of the respiratory tract. Annu Rev Microbiol. 2015;69:425–44. https://doi.org/10.1146/annurev-micro-091014-104209.
Campbell BR, Gonzalez Trotter D, Hines CD, Li W, Patel M, Zhang W, et al. In vivo imaging in pharmaceutical development and its impact on the 3Rs. ILAR J. 2016;57:212–20. https://doi.org/10.1093/ilar/ilw019.
Richter SH. Challenging current scientific practice: how a shift in research methodology could reduce animal use. Lab Anim. 2024;53:9–12. https://doi.org/10.1038/s41684-023-01308-9.
Doyle TC, Burns SM, Contag CH. In vivo bioluminescence imaging for integrated studies of infection. Cell Microbiol. 2004;6:303–17. https://doi.org/10.1111/j.1462-5822.2004.00378.x.
Hutchens M, Luker GD. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol. 2007;9:2315–22. https://doi.org/10.1111/j.1462-5822.2007.00995.x.
Jackson-Litteken CD, Di Venanzio G, Janet-Maitre M, Castro IA, Mackel JJ, Wilson LD, et al. A chronic Acinetobacter baumannii pneumonia model to study long-term virulence factors, antibiotic treatments, and polymicrobial infections. Nat Commun. 2025;16:7617. https://doi.org/10.1038/s41467-025-62655-4.
Hunter P. Illuminating human disease: the potential of in vivo imaging for preclinical research and diagnostics. EMBO Rep. 2019;20:e49195 https://doi.org/10.15252/embr.201949195.
Yamaguchi D, Oki K, Kaya Y, Sakairi Y, Morita Y, Kamoshida G. Deep-tissue in vivo imaging using bioluminescence in a mouse infection model and the path to high sensitivity with near-infrared luminescence. Microbiol Immunol. 2025;69:377–83. https://doi.org/10.1111/1348-0421.13225.
Na SH, Jeon H, Oh MH, Kim YJ, Chu M, Lee IY et al. Therapeutic effects of inhibitor of ompA expression against Carbapenem-resistant Acinetobacter baumannii strains. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms222212257.
Na SH, Oh MH, Jeon H, Lee YK, Lee B, Shin M, et al. Imaging of bioluminescent Acinetobacter baumannii in a mouse pneumonia model. Microb Pathog. 2019;137:103784 https://doi.org/10.1016/j.micpath.2019.103784.
Munder A, Wolbeling F, Klockgether J, Wiehlmann L, Tummler B. In vivo imaging of bioluminescent Pseudomonas aeruginosa in an acute murine airway infection model. Pathog Dis. 2014;72:74–7. https://doi.org/10.1111/2049-632X.12184.
Liu S, Su Y, Lin MZ, Ronald JA. Brightening up biology: advances in luciferase systems for in vivo imaging. ACS Chem Biol. 2021;16:2707–18. https://doi.org/10.1021/acschembio.1c00549.
Saito-Moriya R, Nakayama J, Kamiya G, Kitada N, Obata R, Maki SA et al. How to select firefly luciferin analogues for in vivo imaging. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms22041848.
Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001;19:316–7. https://doi.org/10.1038/86684.
Yamaguchi D, Kamoshida G, Kawakubo S, Azuma S, Tsuji T, Kitada N, et al. Near-infrared in vivo imaging system for dynamic visualization of lung-colonizing bacteria in mouse pneumonia. Microbiol Spectr. 2024;12:e0082824 https://doi.org/10.1128/spectrum.00828-24.
Sykes EME, Deo S, Kumar A. Recent advances in genetic tools for Acinetobacter baumannii. Front Genet. 2020;11:601380. https://doi.org/10.3389/fgene.2020.601380.
Aron AT, Heffern MC, Lonergan ZR, Vander Wal MN, Blank BR, Spangler B, et al. In vivo bioluminescence imaging of labile iron accumulation in a murine model of Acinetobacter baumannii infection. Proc Natl Acad Sci USA. 2017;114:12669–74. https://doi.org/10.1073/pnas.1708747114.
FDA. Microbiological data for systemic antibacterial drug products — development, analysis, and presentation guidance for industry. 2018.
Amin IM, Richmond GE, Sen P, Koh TH, Piddock LJ, Chua KL. A method for generating marker-less gene deletions in multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 2013;13:158 https://doi.org/10.1186/1471-2180-13-158.
Trebosc V, Gartenmann S, Royet K, Manfredi P, Totzl M, Schellhorn B, et al. A novel genome-editing platform for drug-resistant Acinetobacter baumannii reveals an AdeR-unrelated tigecycline resistance mechanism. Antimicrob Agents Chemother. 2016;60:7263–71. https://doi.org/10.1128/AAC.01275-16.
Glick BR. Metabolic load and heterologous gene expression. Biotechnol Adv. 1995;13:247–61. https://doi.org/10.1016/0734-9750(95)00004-a.
Ducas-Mowchun K, De Silva PM, Crisostomo L, Fernando DM, Chao TC, Pelka P et al. Next generation of Tn7-based single-copy insertion elements for use in multi- and pan-drug-resistant strains of Acinetobacter baumannii. Appl Environ Microbiol. 2019;85. https://doi.org/10.1128/AEM.00066-19.
Intorcia V, Sava RL, Schroeder GP, Gebhardt MJ. A series of vectors for inducible gene expression in multidrug-resistant Acinetobacter baumannii. Appl Environ Microbiol. 2024;90:e0047424. https://doi.org/10.1128/aem.00474-24.
Arrazuria R, Kerscher B, Huber KE, Hoover JL, Lundberg CV, Hansen JU, et al. Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents. Front Microbiol. 2022;13:988728 https://doi.org/10.3389/fmicb.2022.988728.
Gibson B, Wilson DJ, Feil E, Eyre-Walker A. The distribution of bacterial doubling times in the wild. Proc Biol Sci. 2018;285. https://doi.org/10.1098/rspb.2018.0789.
Chart H, Griffiths E. Microbial Growth and Nutrition in the Host. Amsterdam: Elsevier; 2002.
Armstrong SK. Bacterial metabolism in the host environment: pathogen growth and nutrient assimilation in the mammalian upper respiratory tract. Microbiol Spectr. 2015;3. https://doi.org/10.1128/microbiolspec.MBP-0007-2014.
Healy C, Munoz-Wolf N, Strydom J, Faherty L, Williams NC, Kenny S, et al. Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease. Respir Res. 2021;22:133 https://doi.org/10.1186/s12931-021-01722-y.
Alikhani MS, Nazari M, Hatamkhani S. Enhancing antibiotic therapy through comprehensive pharmacokinetic/pharmacodynamic principles. Front Cell Infect Microbiol. 2025;15:1521091. https://doi.org/10.3389/fcimb.2025.1521091.
Mak WY, He Q, Yang W, Xu N, Zheng A, Chen M, et al. Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives. Adv Drug Deliv Rev. 2024;214:115447. https://doi.org/10.1016/j.addr.2024.115447.
Pereira LC, Fatima MA, Santos VV, Brandao CM, Alves IA, Azeredo FJ. Pharmacokinetic/pharmacodynamic modeling and application in antibacterial and antifungal pharmacotherapy: a narrative review. Antibiotics. 2022;11. https://doi.org/10.3390/antibiotics11080986.
Rayner CR, Smith PF, Andes D, Andrews K, Derendorf H, Friberg LE, et al. Model-informed drug development for anti-infectives: state of the art and future. Clin Pharmacol Ther. 2021;109:867–91. https://doi.org/10.1002/cpt.2198.
Harris G, Kuo Lee R, Lam CK, Kanzaki G, Patel GB, Xu HH, et al. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother. 2013;57:3601–13. https://doi.org/10.1128/AAC.00944-13.
Wang J, Hu H, Wang Q, Zhu T, Ren X, Jiang W, et al. A novel genus of virulent phage targeting Acinetobacter baumannii: efficacy and safety in a murine model of pulmonary infection. PLoS Pathog. 2025;21:e1013268 https://doi.org/10.1371/journal.ppat.1013268.
He P, Li X, Guo X, Bian X, Wang R, Wang Y, et al. Pharmacokinetics and pharmacodynamics of a novel vancomycin derivative LYSC98 in a murine thigh infection model against Staphylococcus aureus. Infect Drug Resist. 2023;16:1019–28. https://doi.org/10.2147/IDR.S399150.
Andes D, Craig WA. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother. 2003;47:3935–41. https://doi.org/10.1128/AAC.47.12.3935-3941.2003.
Lepak AJ, Zhao M, Andes DR. Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus. Antimicrob Agents Chemother. 2017;61. https://doi.org/10.1128/AAC.00281-17.
Guo C, Liao X, Wang M, Wang F, Yan C, Xiao X, et al. In vivo pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Streptococcus suis serotype 2 at varied initial inoculum sizes. Antimicrob Agents Chemother. 2016;60:1114–20. https://doi.org/10.1128/AAC.02065-15.
Kuchimaru T, Iwano S, Kiyama M, Mitsumata S, Kadonosono T, Niwa H, et al. A luciferin analogue generating near-infrared bioluminescence achieves highly sensitive deep-tissue imaging. Nat Commun. 2016;7:11856. https://doi.org/10.1038/ncomms11856.
Kamoshida G, Akaji T, Takemoto N, Suzuki Y, Sato Y, Kai D, et al. Lipopolysaccharide-deficient Acinetobacter baumannii due to colistin resistance is killed by neutrophil-produced lysozyme. Front Microbiol. 2020;11:573 https://doi.org/10.3389/fmicb.2020.00573.
Kamoshida G, Yamaguchi D, Kaya Y, Yamakado T, Yamashita K, Aoyagi M, et al. Development of a novel bacterial production system for recombinant bioactive proteins completely free from endotoxin contamination. PNAS Nexus. 2024;3:pgae328 https://doi.org/10.1093/pnasnexus/pgae328.
Jie J, Chu X, Li D, Luo Z. A set of shuttle plasmids for gene expression in Acinetobacter baumannii. PLoS One. 2021;16:e0246918 https://doi.org/10.1371/journal.pone.0246918.
